wegovy tirzepatide vs Mounjaro: Which weight-loss injection is right for you? Wegovy® Demonstrates Superior Cardiovascular Benefit

Batch identification for traceability

By Vital Nutrients

Semaglutide may safeguard the heart even without significant weight loss.

In a significant milestone for type 2 diabetes care, Novo Nordisk has unveiled full results from its SOUL cardiovascular outcomes trial, confirming that oral semaglutide (14 mg) reduces the risk of major adverse cardiovascular events (MACE) by 14 per cent compared to placebo in adults with type 2 diabetes and existing cardiovascular and/or chronic kidney disease.The findings, presented at the American College of Cardiology's (ACC) Annual Scientific Session and Expo in Chicago, and simultaneously published in the New England Journal of Medicine, mark a major advancement in cardiometabolic treatment

Now it has been shown that limited experimental data can be used to train sophisticated machine learning models to accurately predict the activity of previously uncharacterized peptide ligand variants.

Ulcerative colitis is a long-term condition where the inner lining of the large intestine (colon and rectum) becomes inflamed and develops ulcers